2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3266 Targeting the pCREB-JAK2-BCL2 regulatory network in high-risk T-ALL

Yangping Wu, PhD, Anni Lu2, Tianfeng Liu3, Yongjuan Duan4, Meihui Yi5, Ziqi Hu6, Nuo Li7, Linlin Jin8, Yan Zhu9, Ye Guo10, Li Zhang11, Yumei Chen12, Xiaojuan Chen13, Yao Zou14, Changya Chen, PhD15, Peng Wu, PhD16, Wenyu Yang17, Xiaofan Zhu, MD18, Yingchi Zhang19, Jingliao Zhang, MD20
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
9 State Key Laboratory of Digital Medical Engineering, Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Hainan, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China
20 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China

Background

T-cell acute lymphoblastic leukemia (T-ALL) remains an aggressive malignancy with poor prognosis for high-risk patients, highlighting the need for robust risk stratification and targeted therapies. Here, we identify phosphorylated CREB (pCREB) as a functional biomarker of high-risk T-ALL and define a core CREB-JAK2-BCL2 regulatory network that provides a rationale for a novel combination therapy.

Methods

We performed Luminex-based multiplex immunoassay to quantify TCR pathway phosphorylation (pCD3e, pLCK, pZAP70, pLAT, pERK/MAPK, and pCREB) in 31 primary newly diagnosed T-ALL samples, integrating bulk RNA-seq and clinical outcome data. We applied NetBID2 algorithm to infer gene activity, selected highly variable genes and drivers, performed correlation analysis with pCREB levels, ranked by random forest, and used LASSO Cox regression to build a prognostic model. The pCREB signature was validated in two independent cohorts (institutional, n=44; TARGET, n=259). Mechanistic studies included CREB ChIP-seq in Jurkat cells, ChIP-qPCR/H3K27ac ChIP-qPCR validation, scRNA-seq projection onto a normal T-cell development reference, and NetBID2-based activity correlation analyses. Therapeutic efficacy of CHZ868 (JAK2 inhibitor) and Venetoclax (BCL2 inhibitor) was evaluated in vitro, ex vivo across primary samples, and in vivo in two T-ALL PDX models. Synergy was quantified using HSA model (SynergyFinder).

Results

Luminex data showed that pCREB levels significantly correlated with the other five phospho-proteins, and the pCREB-high subgroup (n=9) exhibited significantly worse relapse-free survival (RFS) and overall survival (OS) compared to pCREB-low (n=22). To translate this into a transcriptomic signature, we established a prognostic model comprising 9 features. This pCREB signature score (pCREBsig) distinguished RFS and OS in the discovery cohort and validated in two independent cohorts, with the high-score groups showing significantly poorer survival. The pCREBsig score also positively correlated with bone marrow blast percentages in both discovery and validation cohorts, linking hyperactive pCREB to higher initial tumor burden.

Differential gene expression and activity analyses between pCREB-high and -low subgroups identified dysregulated genes (e.g., JAK1, JAK2, CDKN2B, KRAS) and drivers (e.g., STAT3, TP53). GSEA revealed aberrant pathways mainly involving TCR signaling, JAK-STAT signaling, and metabolic reprogramming. GSVA confirmed enrichment of immature T-cell signatures in the pCREB-high group. Projecting scRNA-seq data of six T-ALL patients onto a normal T-cell development reference revealed that T-ALL blasts accumulated at T-lineage progenitors and LMPPs, with a reversal of CREB1 expression dynamics: highest in the most primitive LMPP-like blasts and diminishing with pseudotime, coincident with high JAK2 expression at the same stage. We validated CREB occupancy at JAK2, BCL2, LEF1, and TLX3 loci by ChIP-qPCR and H3K27ac ChIP-qPCR, with significant enrichment of the canonical CREB motif. NetBID2-inferred activities of CREB1_TF, JAK2_SIG, and BCL2_SIG showed consistent significant positive pairwise correlations across the discovery cohort and two validation cohorts, defining a core regulatory circuit.

Guided by this network, we targeted upstream TCR signaling with Dasatinib, and downstream effectors with the type II JAK2 inhibitor CHZ868 and the BCL2 inhibitor Venetoclax. The triple combination showed potent HSA synergy (peak synergy scores >40) in Jurkat, MOLT-4, and KOPT-K1 cell lines in vitro. Dual combinations also exhibited significant efficacy, with CHZ868 plus Venetoclax showing robust inhibition and synergy across six primary T-ALL samples spanning all developmental subtypes. Given limited clinical response to Dasatinib, we focused on CHZ868 plus Venetoclax. In two T-ALL PDX models resistant to each single agent, oral administration of CHZ868 plus Venetoclax significantly slowed peripheral blood blast increase and prolonged survival compared to vehicle or monotherapy.

Conclusions

Our findings establish pCREB as a prognostic biomarker and a central node of an oncogenic network, and demonstrate that co-targeting JAK2 and BCL2 overcomes single-agent resistance, providing a rational, network-informed therapeutic strategy for high-risk T-ALL.

Jingliao Zhang, MD: No relevant conflicts of interest to declare.